Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 365

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 365
---
, for all periods following the Closing Date
of the Reverse Merger, the results of operations of the combined company are included in the Company’s financial statements.

Other Key Corporate Events

On November 30, 2020, we filed amended and restated
articles of incorporation with the Secretary of State of the State of Delaware (“Amended and Restated Certificate”) to change
the name of the Company to Mosaic ImmunoEngineering, Inc. (“Name Change”) to align the Company’s corporate name with
its new strategic direction, to implement a 1-for-500 reverse stock split (“Reverse Stock Split”), and to reduce the number
of authorized shares of common stock from 600 million to 100 million. The Reverse Stock Split was effective on December 2, 2020. All share
numbers and preferred stock conversion numbers included herein have been retroactively adjusted to reflect the 1-for-500 Reverse Stock
Split. On December 30, 2020, we changed our fiscal year end from May 31 to December 31.

Our funding has primarily come from the issuance of
convertible notes. On May 7, 2021 and February 18, 2022, we issued unsecured convertible promissory notes in the aggregate principal amount
of $575,000 and $341,632, respectively (see Note 7 to the accompanying consolidated financial statements).

On July 6, 2022, we entered into a redemption agreement
(the “Redemption Agreement”) with Holocom, Inc. (“Holocom”) pursuant to which we requested full redemption of
our 2,100,000 shares of Series A Preferred Stock at a redemption price of $0.40 per share, provided Holocom has sufficient capital to
redeem the underlying shares. As of December 31, 2023, we redeemed in aggregate, 2,100,000 shares of Series A Preferred Stock, in exchange
for aggregate net proceeds received by us of $776,000 (see Note 4 to the accompanying consolidated financial statements). As of December
31, 2023, Holocom had no further obligations to us under the Redemption Agreement or any other arrangement and therefore there were no
proceeds received during the year ended December 31, 2024.

On April 26, 2024, we entered into a binding term
sheet (“Binding Term Sheet”) with Oncotelic Therapeutics, Inc. (“Oncotelic”) pursuant to which we intend to acquire